215 related articles for article (PubMed ID: 21858654)
41. Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection.
Touma W; Hoostal S; Peterson RA; Wiernik A; SantaCruz KS; Lou E
J Clin Neurosci; 2017 Jul; 41():75-77. PubMed ID: 28291643
[TBL] [Abstract][Full Text] [Related]
42. MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.
Salehi F; Scheithauer BW; Kros JM; Lau Q; Fealey M; Erickson D; Kovacs K; Horvath E; Lloyd RV
J Neurooncol; 2011 Sep; 104(3):647-57. PubMed ID: 21311951
[TBL] [Abstract][Full Text] [Related]
43. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
44. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
45. Anti-VEGF therapy in pituitary carcinoma.
Ortiz LD; Syro LV; Scheithauer BW; Ersen A; Uribe H; Fadul CE; Rotondo F; Horvath E; Kovacs K
Pituitary; 2012 Sep; 15(3):445-9. PubMed ID: 21918831
[TBL] [Abstract][Full Text] [Related]
46. Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.
Pivonello C; Patalano R; Solari D; Auriemma RS; Frio F; Vitulli F; Grasso LFS; Di Cera M; De Martino MC; Cavallo LM; Cappabianca P; Colao A; Pivonello R
Endocrine; 2018 Dec; 62(3):663-680. PubMed ID: 30066286
[TBL] [Abstract][Full Text] [Related]
47. North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
Sarkaria JN; Galanis E; Wu W; Peller PJ; Giannini C; Brown PD; Uhm JH; McGraw S; Jaeckle KA; Buckner JC
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):468-75. PubMed ID: 20864273
[TBL] [Abstract][Full Text] [Related]
48. Is there a role for early chemotherapy in the management of pituitary adenomas?
Lin AL; Sum MW; DeAngelis LM
Neuro Oncol; 2016 Oct; 18(10):1350-6. PubMed ID: 27106409
[TBL] [Abstract][Full Text] [Related]
49. HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy.
Kun Z; Yuling Y; Dongchun W; Bingbing X; Xiaoli L; Bin X
Technol Cancer Res Treat; 2016 Dec; 15(6):NP95-NP104. PubMed ID: 26647409
[TBL] [Abstract][Full Text] [Related]
50. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
[TBL] [Abstract][Full Text] [Related]
51. Use of temozolomide in aggressive pituitary tumors: case report.
Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
[TBL] [Abstract][Full Text] [Related]
52. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
[TBL] [Abstract][Full Text] [Related]
53. Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.
Zatelli MC; Minoia M; Filieri C; Tagliati F; Buratto M; Ambrosio MR; Lapparelli M; Scanarini M; Degli Uberti EC
J Clin Endocrinol Metab; 2010 Feb; 95(2):968-76. PubMed ID: 19965918
[TBL] [Abstract][Full Text] [Related]
54. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
Mabuchi S; Kawase C; Altomare DA; Morishige K; Sawada K; Hayashi M; Tsujimoto M; Yamoto M; Klein-Szanto AJ; Schilder RJ; Ohmichi M; Testa JR; Kimura T
Clin Cancer Res; 2009 Sep; 15(17):5404-13. PubMed ID: 19690197
[TBL] [Abstract][Full Text] [Related]
55. Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide.
Batisse M; Raverot G; Maqdasy S; Durando X; Sturm N; Montoriol PF; Kemeny JL; Chazal J; Trouillas J; Tauveron I
Cancer Invest; 2013 Mar; 31(3):190-6. PubMed ID: 23477586
[TBL] [Abstract][Full Text] [Related]
56. Atypical, invasive, recurring Crooke cell adenoma of the pituitary.
Rotondo F; Cusimano M; Scheithauer BW; Coire C; Horvath E; Kovacs K
Hormones (Athens); 2012; 11(1):94-100. PubMed ID: 22450349
[TBL] [Abstract][Full Text] [Related]
57. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Hirohata T; Ishii Y; Matsuno A
Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
[TBL] [Abstract][Full Text] [Related]
58. Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
Campderá M; Palacios N; Aller J; Magallón R; Martín P; Saucedo G; Lilienfeld H; Estrada J
Pituitary; 2016 Apr; 19(2):158-66. PubMed ID: 26586560
[TBL] [Abstract][Full Text] [Related]
59. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
[TBL] [Abstract][Full Text] [Related]
60. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
Ma BB; Lui VW; Hui EP; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Chan AT
Invest New Drugs; 2010 Aug; 28(4):413-20. PubMed ID: 19471857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
